Article
Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
Antimicrobial agents and chemotherapy - 21 Jun 2022
Diamond Tracy L, Ngo Winnie, Xu Min, Goh Shih Lin, Rodriguez Silveria, Lai Ming-Tain, Asante-Appiah Ernest, Grobler Jay A
Abstract excerpt
Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that inhibits human immunodeficiency virus (HIV) reverse transcription by blocking reverse transcriptase (RT) translocation on the primer:template. ISL is being developed for the treatment of HIV-1 infection. To expand our knowledge of viral variants that may confer reduced susceptibility to ISL, resistance selection studies...
Topics
Join the communities discussing this publication.